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In 2007 the Maryland Medical Examiner noted a potential
cluster of fatal vascular access hemorrhages among
hemodialysis patients, many of whom died outside of a
health-care setting. To examine the epidemiology of fatal
vascular access hemorrhages, we conducted a retrospective
case review in District of Columbia, Maryland, and Virginia
from January 2000 to July 2007 and a case–control study.
Records from the Medical Examiner and Centers for Medicare
and Medicaid Services were reviewed, from which 88 patients
were identified as fatal vascular access hemorrhage cases.
To assess risk factors, a subset of 20 cases from Maryland
was compared to 38 controls randomly selected among
hemodialysis patients who died from non-vascular access
hemorrhage causes at the same Maryland facilities. Of the
88 confirmed cases, 55% hemorrhaged from arteriovenous
grafts, 24% from arteriovenous fistulas, and 21% from central
venous catheters. Of 82 case-patients with known location of
hemorrhage, 78% occurred at home or in a nursing home. In
the case–control analysis, statistically significant risk factors
included the presence of an arteriovenous graft, access-
related complications within 6 months of death, and
hypertension; presence of a central venous catheter was
significantly protective. Psychosocial factors and
anticoagulant medications were not significant risk factors.
Effective strategies to control vascular access hemorrhage in
the home and further delineation of warning signs are
needed.
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In 2007, 341,000 patients were treated with hemodialysis for
end-stage renal disease (ESRD) in the United States.1
Hemodialysis requires one of several vascular access types,
including arteriovenous (AV) fistulas, AV grafts, and central
venous catheters. An AV fistula is a native vessel connection
between an artery and a vein; an AV graft typically employs
polytetrafluorethylene to establish a synthetic connection
between an artery and a vein; and a central venous catheter is
a synthetic tube inserted into a vein. Hemodialysis accesses
are subject to complications such as clotting, stenosis,
infection, and hemorrhage.2–4 Access complications are
common among hemodialysis patients, but they are usually
not life-threatening. The etiology and epidemiology of fatal
vascular access hemorrhage (FVAH) in the United States has
not been well described or studied.
In the past 35 years, single case reports of FVAH have been
published describing FVAH by suicide, needle or catheter
separations occurring during dialysis, or spontaneous rup-
ture.5–9 Current prevention measures focus on solutions to
needle or catheter separation during dialysis (e.g., constant
visualization of access during dialysis or alarms to detect
blood-soaked bandages and safety clips and clamps).10
However, needle or catheter separations only account for a
portion of FVAH. Risk factors and prevention strategies
for seemingly spontaneous ruptures of AV grafts and fistulas
have not been described. The only published case series
on FVAH among hemodialysis patients described three
deaths in Australia;11 case descriptions revealed clots and
infection in the patients who had hemorrhaged from AV
fistulas and grafts, respectively, and suicide in a patient who
had intentionally cut a central venous catheter used for
hemodialysis.
In 2007, staff at the Centers for Disease Control and
Prevention (CDC) was alerted to a potential cluster of
deaths from hemorrhage of vascular access among hemo-
dialysis patients in Maryland. A sample FVAH case descrip-
tion and Medical Examiner findings are depicted
in Figures 1 and 2. At that time, a retrospective case review
conducted by the Maryland Medical Examiner showed 24
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FVAH cases over a 6-year period, but no common risk factors
were identified.12,13 In 2008, the CDC launched a regional
investigation into FVAH. The goals of the investigation were
to describe characteristics of hemodialysis patients who died
from FVAH in District of Columbia, Maryland, and Virginia
from January 2000 to July 2007, describe circumstances
surrounding FVAH deaths, and identify risk factors asso-
ciated with the occurrence of FVAH.
The Maryland Medical Examiner review reported a
large proportion of FVAH cases caused by vascular access
rupture occurring outside of a health-care setting. On the
basis of existing published reports, informal provider inter-
views, and theoretical rationale, three broad hypotheses
for underlying causes of seemingly spontaneous ruptures
resulting in FVAH were considered. These hypotheses were:
(1) excessive anticoagulation resulting from high-dose
heparin infusions used during dialysis or from systemic
anticoagulant or antiplatelet medication regimens;14 (2)
intentional patient manipulation of the access site;5,6,10
and (3) compromised integrity of vascular access due to
complications (e.g., stenosis, clotting, ulceration, infection,
and non-fatal hemorrhage) or invasive procedures.3,15
RESULTS
During 2000–2006, 1654 hemodialysis patients died in the
United States from FVAH according to the Centers for
Medicare and Medicaid Services (CMS) End-Stage Renal
Disease Notification of Death data. In all, 71 of these deaths
were coded as ‘Hemorrhage of dialysis circuit’, 1581 were
coded as ‘Hemorrhage of vascular access’, and two were coded
as both. During this time period, 430,887 hemodialysis
patients died in the United States. Thus, according to
CMS records, FVAH contributed to approximately 0.4% of
hemodialysis patient deaths.
For the regional query of CMS End-Stage Renal Disease
data, 142 FVAH deaths were identified in District of
Columbia, Maryland, and Virginia. Of the 142 record
requests made to outpatient providers, 89 (63%) records
were submitted to investigators. Of these 89 patients,
investigators confirmed 67 (76%) as FVAH. All 21 of the
additional cases identified by the Maryland Medical Exam-
iner were confirmed FVAH upon record review; five cases
identified by the Maryland Medical Examiner had been also
identified and confirmed from the CMS data query and
record review. In total, 88 confirmed FVAH cases were
identified.
The 88 confirmed FVAH cases occurred in patients treated
at 58 different dialysis facilities in District of Columbia,
Maryland, and Virginia, with no more than three deaths
occurring at any one facility. The median number of cases
per year was 11 (range 7–16) with the most cases occurring
during 2004. Among confirmed cases, 56% were male,
the median age was 64 years (range, 28–89), and 73%
were African-American (Table 1). In all, 9% had a recent
history of injection drug or cocaine use and 32% had been
taking systemic anticoagulant or antiplatelet medications.
Of case-patients with available information on type of access
resulting in fatal hemorrhage (n¼ 86), 55% hemorrhaged
A 56-year-old male was in his bathroom at home when he started 
bleeding profusely from his thigh arteriovenous (AV) graft. He 
applied compression to the site and told his mother to call 911. The 
patient was transported to the emergency room, but was 
pronounced dead on arrival. The patient had documented stenosis 
of his AV graft 2 weeks earlier. He had been last dialyzed 2 days 
before death and at that time had a clot over the access noted 
when dialysis began. The Medical Examiner determined that his 
access had eroded and ruptured.
Figure 1 |Description of a fatal vascular access hemorrhage
(FVAH) case history as documented in outpatient medical
records and Medical Examiner report.
a
b
c
Figure 2 |Photos taken by the Maryland Medical Examiner of
a ruptured fistula (a), and of ulcerated access sites (b, c)
following fatal vascular access hemorrhage (FVAH). Photos
courtesy of Donna Vincenti, Office of the Chief Medical Examiner.
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from an AV graft, 24% from an AV fistula, and 21% from a
central venous catheter. Of those whose location at the time
of hemorrhage was known (n¼ 82), 78% hemorrhaged at
home, in assisted living, or in a nursing home. Of cases that
occurred at home (n¼ 57), 26% (n¼ 15) of patients were
alone at the time of the hemorrhage and Emergency Medical
Services were called in 70% (n¼ 40).
For 83% of cases, a ‘rupture/dislodgement’ occurred while
the patient was not undergoing hemodialysis treatment or
another health-care procedure. The vast majority of FVAH
occurring in patients with AV grafts or fistulas were access
ruptures (91% and 93%, respectively). Of 25 AV graft and
fistula cases reviewed by the MDMedical Examiner (thus with
detailed assessment of hemorrhage site), 72% (n¼ 18) had
evidence of access erosion. Three (4%) of the 71 cases
classified as rupture/dislodgement had documentation of self-
harm as a contributing cause of hemorrhage or death. In all,
10 (12%) FVAH cases were categorized as perforation during
a health-care procedure (Table 2); most had central venous
catheters that were perforated during a health-care procedure
and resulted in massive bleeding. Only five (6%) FVAH cases
resulted from dislodgement or separation of access needles or
other components of the hemodialysis circuit during treat-
ment (‘needle/catheter separation during dialysis’).
Of cases with complete outpatient dialysis records and
specified access site of fatal hemorrhage (n¼ 62), 58%
experienced vascular access complications in the 6 months
preceding death; the most common complications included
infection and previous history of vascular access hemorrhage.
Complications at the site of fatal vascular access hemorrhage
were more common for patients who hemorrhaged from an AV
fistula or graft (71% and 68%, respectively) than for patients
who hemorrhaged from a central venous catheter (18%).
In the case–control analyses (n¼ 58, 20 cases and 38
controls), no significant differences were found in demo-
graphic characteristics, mental health diagnoses, non-compli-
ant behavior, socioeconomic status, or anticoagulation
regimen. Bivariate analyses did demonstrate differences in
age-adjusted Charlson Comorbidity Index16 (P¼ 0.02), with
case-patients having fewer comorbidities than controls overall;
however, when comorbidities were tested individually, a higher
percentage of case-patients had hypertension when compared
to controls (Table 3). Case-patients had also received mainte-
nance hemodialysis for a median of 5 years as opposed to
2 years for controls (P¼ 0.02). More case-patients (55%) were
dialyzed through an AV graft at last dialysis as opposed to
controls (16%) (Po0.01), and fewer case patients were
dialyzed through a central venous catheter (15%) as opposed
to controls (53%) (Po0.01). In addition, 75% of case-patients
experienced an access-related complication within 6 months of
death compared with 24% of controls (Po0.001). In an
unadjusted logistic regression model, cases had significantly
higher odds of having an AV graft at last dialysis (odds ratio¼
6.9; 95% confidence interval (CI)¼ 1.9–24.3). Adjusted odds
ratios for the association between AV graft use at last dialysis
and FVAH remained significant and did not drop below 5.4
when hypertension, time on dialysis, age-adjusted Charlson
Comorbidity Index, and any complication were independently
added to multivariable models to test for confounding.
DISCUSSION
This investigation represents the first epidemiological
description of FVAH among hemodialysis patients in the
Table 1 | Demographics and circumstances surrounding
deaths of hemodialysis patients with confirmed fatal vascular
access hemorrhage in the District of Columbia, Maryland,
and Virginia, 2000–2007
Characteristic (n)a n or median % or range
State of residence (n=88)
District of Columbia 9 10.2
Maryland 54 61.4
Virginia 25 28.4
Age in years (n=88) 64 28–89
Months of hemodialysis treatment (n=55) 60 4–277
Sex (n=88)
Female 39 44.3
Male 49 55.7
Race (n=88)
African-American 64 72.7
Asian 1 1.1
Caucasian 23 26.1
Systemic anticoagulant or antiplatelet medication (n=88)
Aspirin 16 18.2
Warfarin 12 13.6
Other 9 10.2
Any (of above 3) 28 31.8
Illicit drug use (injection drugs or cocaine)
(n=88)
8 9.2
Mental health impairments (n=64)
Dementia/confusion 12 18.8
Depression/anxiety 12 18.8
Other major psychiatric diagnoses 7 10.9
Any (of above 3) 26 40.6
Medical non-compliance (n=64)b 35 54.7
Vascular access type at death (n=86)
CVC 18 20.9
AVF 21 24.4
AVG 47 54.7
Patient location at the time of fatal hemorrhage (n=82)
Residence (home or nursing home) 64 78.1
Hospital 7 8
Dialysis unit or other outpatient center 10 12.2
Other (car) 1 1.2
Patient location at the time of death (n=87)
Residence (home or nursing home) 24 27.6
Hospital 62 71.3
Dialysis unit 1 1.2
Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central
venous catheter.
aBecause data were gathered from different sources, denominators reflect the
number of subjects for which information was available.
bNotation in chart of missed appointments, leaving early against medical advice,
non-compliance with dietary instruction, or non-compliant with medication.
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United States. While FVAH appears to be a relatively rare
cause of death (0.4% of all end-stage renal disease deaths), it
accounted for over 1600 deaths nationwide from 2000 to
2006 according to the cause of death information reported
by hemodialysis providers to CMS. Our regional investi-
gation suggests that this national number is potentially an
Table 2 | Characterization of fatal vascular access hemorrhage events and documented complications within 6 months of death
stratified by CVC, AVF, or AVG at the site of fatal hemorrhage
Total,
n (%)
CVC,
n (%)
AVF,
n (%)
AVG,
n (%)
Categorization (n=86)a
Rupture/dislodgement 71 (82.6) 8 (44.4) 19 (90.5) 44 (93.6)
Perforation during a health-care procedure 10 (11.6) 9 (50.0) 1 (4.8) 0 (0.0)
Needle/catheter separation during dialysis 5 (5.8) 1 (5.6) 1 (4.8) 3 (6.4)
Vascular access complications within 6 months of death (n=62)b
Clotting 11 (17.4) 1 (9.1) 1 (7.1) 9 (24.3)
Stenosis 10 (16.1) 0 (0) 4 (28.6) 6 (16.2)
Aneurysm/pseudoaneurysm 7 (11.3) 0 (0) 4 (28.6) 3 (8.1)
Infection 14 (22.6) 1 (9.1) 5 (35.7) 8 (21.6)
Vascular access hemorrhage 12 (19.4) 1 (9.1) 4 (28.6) 7 (18.2)
Any complication (of above 5) 36 (58.1) 2 (18.2) 10 (71.4) 24 (67.6)
Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter; FVAH, fatal vascular access hemorrhage.
aOf the 88 confirmed FVAH cases, two were excluded because they had multiple accesses at the time of death with no documentation to distinguish which was the site of the
fatal hemorrhage.
b64 cases had an outpatient record available from their dialysis treatment center available for review to determine complications in the 6 months preceding death; of these,
62 had documentation of the site of fatal hemorrhage.
Table 3 | Bivariate comparison of fatal vascular access hemorrhage deaths (cases) to and controls (deaths from other causes)
from 17 Maryland hemodialysis facilities
Cases, n=20 Controls, n=38
Difference
Median (n) Range (%) Median (n) Range (%) P-value
Age 64 31–89 70 31–92 0.19
Male 10 50.0 26 68.4 0.17
Race: African-American 11 55.0 14 36.8 0.18
Charlson score (age-adjusted) 6 2–10 8 3–13 0.02
Comorbidities
Anemia 14 70.0 33 86.8 0.16
Hypertension 18 90.0 22 57.9 0.01
Diabetes 9 45.0 17 44.7 0.99
Cerebrovascular disease 2 10.0 7 18.4 0.48
Months of hemodialysis treatment 68 4–277 34 0–117 0.02
Access used at last dialysis
AVG 11 55.0 6 15.8 o0.01
AVF 5 25.0 10 26.4 0.91
CVC 3 15.0 20 52.6 o0.01
Any systemic anticoagulant/antiplatelet medication 8 40.0 22 57.9 0.20
Heparin used: Last dialysis
Catheters (circuit) 5000 2–6000 2625 0–8000 0.36
Catheters (locks) 2000 0–10,000 0 0–21,000 1.00
Grafts/fistulas 4000 0–8500 2550 0–13,000 0.57
Medical non-compliance 10 50.0 17 44.7 0.94
Illicit drug use 3 15.0 1 2.6 0.07
Any mental health impairment 9 45.0 14 36.8 0.41
Median household incomea US$44,554 US$21–68K US$51,176 US$16–140K 0.25
Complication
Clotting 8 40.0 3 7.9 o0.01
Stenosis 4 20.0 3 7.9 0.19
Infection 10 50.0 6 15.8 0.01
Previous vascular access hem 2 10.0 0 0.0 0.98
Any complication 15 75.0 9 23.7 o0.001
Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter.
aMedian household income by provider zip code.
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underestimate as the CMS data identified only a fraction
(24%) of the FVAH deaths identified independently by the
Maryland Medical Examiner during 2000–2007.
Fatal vascular access hemorrhage events primarily oc-
curred in patients with AV grafts and AV fistulas and were
likely related to complications affecting the mechanical
integrity of the access. Relatively few patients had any of
the hypothesized risks for FVAH, such as over-anticoagula-
tion, injection drug use, or suicidal intent. Although the
case–control analyses was not powered to fully address
multiple sources of confounding, there were no unadjusted
differences in reported doses of intra-dialysis anticoagulant
or systemic medications that might predispose a patient to
bleeding or in documented psychological illness or medical
non-compliance. Very few FVAH cases were illicit substance
abusers. The FVAH cases did not cluster by facility, which
suggested that these deaths were not a result of specific
providers engaging in high-risk or negligent practices.
Because the cases that prompted this investigation occurred
in the mid-Atlantic region of the United States, the question
of whether patients in this region had appropriate access to
vascular surgeons has been raised; however, the ratio of
vascular surgeons to dialysis patients in Maryland, District of
Columbia, and Virginia is slightly higher than in all other
states combined (1:195 vs. 1:202, respectively), suggesting
that there are more vascular surgeons per ESRD patient in the
study region.17,18
Most (65%) FVAH events occurred at the patient’s home.
For the majority of these cases, another person was at home
with the patient at the time of hemorrhage and emergency
medical services were contacted. Currently available recom-
mendations for hemorrhages occurring in a non-treatment
setting are variable. They include applying gentle pressure
over the access and contacting the dialysis center if bleeding
persists after 20–30min for AV grafts and fistulas,19,20 and
holding pressure for 10min, and then contacting the dialysis
unit for central venous catheters.19–22 These messages are
clearly insufficient to stem major vascular access hemor-
rhages. Means of identifying severe vascular access hemor-
rhage and appropriate measures to take in those situations
need to be communicated to patients. Procedures to limit
in-center hemodialysis-related blood loss, such as continuous
vascular access visualization and clips to prevent needle
dislodgement, are clearly important in preventing FVAH
events; however, the low frequency of events that occurred
from needle/catheter separation during in-center dialysis
underscores the need to develop additional prevention
strategies that extend beyond in-center processes.
Over half of FVAH cases reviewed hemorrhaged from an
AV graft, and AV graft use at last dialysis was significantly
associated with FVAH in the case–control study, even after
controlling for confounding factors. These results support
previous studies that have documented an association
between AV graft use and vascular access complications such
as infection and stenosis7–9 and may reinforce the importance
of quality improvement initiatives such as the CMS Fistula
First Breakthrough Initiative (FFBI), which recommends AV
fistula use over the more complication-prone AV grafts and
central venous catheters.23 Although AV fistula placement is
generally encouraged for maximal patient safety and access
patency, some hemodialysis patients cannot sustain fistula
placement because of poor vasculature.
In case–control analyses, cases had significantly more
vascular access complications documented in the 6 months
before death as compared to controls, which suggests the
possibility of tangible warning signs before FVAH, particu-
larly for patients who have been on dialysis for multiple years.
Despite power limitations that limited the ability to perform
multivariate analyses, the case–control analysis revealed
infection and clotting as significant, unadjusted risk factors
for FVAH. Other complications associated with FVAH, such
as distal history of hemorrhage or specific types of
compromised graft integrity, may also be important to
explore in future analyses. In the absence of well-established
and specific risk factors for FVAH, preventative measures
such as close monitoring and early intervention to address
access complications in general may lead to decreased
probability of FVAH.
This study is subject to certain limitations. First, results of
this analysis may not be adequate to estimate frequency of
FVAH. It is likely that there is underreporting of FVAH on
the CMS Death Notification forms. This was demonstrated
by the findings in Maryland, where only five of 26 cases
identified by the Medical Examiner were similarly identified
in the original CMS database query. Conversely, there were
28 confirmed FVAH cases in Maryland identified by the
CMS query that were not identified by the independent query
by the Maryland Medical Examiner. Independent queries by
the Virginia and District of Columbia Medical Examiners
did not yield any additional cases, suggesting that medical
examiners may not look for, or document completely, these
types of cases. The Maryland Medical Examiner, who
originally brought these cases to the attention of the Centers
for Disease Control and Prevention, may have been able to
identify more cases via retrospective query (compared to
Medical Examiners in other states) due to enhanced
attentiveness to and familiarity with FVAH. Collectively,
under-identification of FVAH cases by both Medical
Examiner and CMS queries is concerning and makes it
difficult to characterize national and regional estimates of
burden.
There were also limitations in the amount of medical
information available for potential FVAH cases. Records
came from different dialysis centers, so patient information
was not uniformly documented, which limited the consis-
tency and completeness of information. Important situa-
tional and risk factor information was often not documented.
For example, especially for ruptures/dislodgements, informa-
tion about situational events immediately before the
hemorrhage and control measures that were undertaken
were often not documented, which limited our ability to fully
characterize these events. In addition, the timing of the calls
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to emergency medical services relative to the FVAH event and
the steps taken to control the hemorrhage were not available,
as most of these cases were not reviewed by the medical
examiner. In addition, in more than half of the cases
reviewed, there was no documentation of date of vascular
access placement, hence limiting our ability to ascertain
duration of use of the vascular access, a potentially important
risk factor.
Finally, we used controls with non-FVAH deaths, which
limited our ability to identify the factors that differentiate
non-fatal from fatal access hemorrhages. Future investiga-
tions should consider a method for identifying ESRD patients
who had non-fatal vascular access hemorrhages, as these
patients would serve as an informative control group. As this
was a public health response investigation, our case–control
study was not sufficiently powered to detect small differences
in the distribution of risk factors between cases and controls,
nor was the study sufficiently powered for robust multiple
regression models.
Conclusions/recommendations
In conclusion, fatal vascular access hemorrhage is a rare but
potentially preventable cause of death in hemodialysis
patients and AV graft use appears to be a risk factor. On
the basis of these findings, nephrologists and medical
examiners should thoroughly investigate these events when
they occur and report them appropriately to CMS. Medical
providers should help to develop and reinforce with their
patients primary and secondary prevention measures for
hemorrhages that occur in the home. Although the
risk factor analysis presented has some methodological
limitations, findings suggest that particular attention should
be paid to hypertensive patients and those who experience
vascular access complications, including infection and
clotting, as they might be a higher risk for FVAH. Future
study is needed to better delineate vascular access hemor-
rhage warning signs and symptoms, as well as the factors that
might predict a fatal hemorrhage versus a non-fatal one.
MATERIALS AND METHODS
To identify possible FVAH deaths, investigators queried a CMS
database containing data from the ESRD Death Notification forms
(CMS ESRD Form 2746). Hemodialysis providers are required to
submit the ESRD Death Notification Form to CMS within 30 days
of patient death. To assess the national scope of FVAH, investigators
queried all patients coded by providers as having died from
‘Hemorrhage of dialysis circuit’ and ‘Hemorrhage of vascular access’
in the United States from January 2000 through December 2006.
For the regional investigation, investigators restricted the query to
patients who were treated in District of Columbia, Maryland, and
Virginia from January 2000 to July 2007. For the regional
investigation, CMS provided CDC investigators with identifying
information so that various record requests could be initiated. Death
Notification data were obtained from CMS under a CDC-CMS Data
Use Agreement.
For the 142 cases identified regionally, investigators from District
of Columbia, Maryland, and Virginia health departments requested
outpatient hemodialysis records for 6 months preceding death. Vital
statistics records, Medical Examiner reports, and emergency depart-
ment or in-patient hospitalization records for those who died at or
en route to a hospital were also requested for all potential cases.
For each potential case identified by the CMS ESRD Death
Notification search, confirmation of death by FVAH was determined
upon review of all available records by a team of CDC and
health department investigators. Confirmation of FVAH required
explicit documentation of hemorrhage from a vascular access site as
a primary or contributing cause of death. Excluded cases did not
have sufficient information to confirm death by FVAH; for example,
if unspecified hemorrhage was noted as a cause of death without
reference to vascular access, the potential case was not considered
‘confirmed’. The Medical Examiner in Maryland performed a search
of electronic records and identified 21 additional potential FVAH
cases that were not identified by the CMS query. Medical examiners
from District of Columbia and Virginia searched but did not
identify additional FVAH cases.
For confirmed FVAH cases, information extracted from available
records included demographic characteristics, comorbidities, details
of vascular access type and placement, complications and proce-
dures involving vascular accesses within 6 months of death,
psychosocial diagnoses, anticoagulation medication, and circum-
stances surrounding death. The presence of access-related complica-
tions, psychological diagnoses, and treatment compliance (i.e.,
missed dialysis sessions or documented non-compliance with
medications or diet) were assessed for cases with complete
outpatient records. Complications were most frequently identified
in technician notes on dialysis flow sheets or in separate provider
assessments found in the outpatient file. Mental health issues were
most frequently identified on medical history sheets or social work
assessments.
A case–control study was initiated 6 months after the
initial record review to assess risk factors for FVAH. A subset of
20 case-patients from Maryland, who were dialyzed at 17 outpatient
facilities owned by the same parent company, was selected for a
case–control study. These cases were selected because of the
availability of records from this company. Controls were selected
from the same 17 facilities to ensure that cases and controls could be
reliably compared with regard to documented risk factors. Selecting
cases and controls from the same company assured consistency
in documentation across facilities belonging to a single parent
company, thereby minimizing the possibility that documentation
differences could be misconstrued as risk factor differences. Controls
were randomly selected from the CMS ESRD Notification of Death
database restricted to dialysis patient deaths from non-FVAH causes
occurring among patients treated at the same facility pool as the
cases. In January 2008, requests were made for 50 control patient
records; 10 were excluded because of incompleteness or unavail-
ability of records, and 2 were excluded because they were peritoneal
dialysis patients (final n¼ 38). Specific comorbidities were
compared for cases and controls, as well as for the Charlson
comorbidity score, which is an index of comorbid medical
conditions.16 Bivariate differences between cases and controls were
calculated using w2 analyses for categorical variables; for continuous
variables, Wilcoxon’s rank-sum tests were used to compare medians
as distributions were not normal. Because this was a public health
response investigation, without an over-riding a priori hypothesis, a
power calculation was not conducted before the study. Hypotheses
were tested regarding individual risk factors. Because of the small
case–control sample size, multivariable logistic regression was used
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to assess the impact of potential confounders (one at a time) for
hypothesized risk factors. All analyses were conducted in SAS 9.1.2
(Cary, NC).
This investigation underwent human subjects’ review by the
Centers for Disease Control and Prevention, was determined not to
be human subjects research, and therefore did not require review by
CDC’s Institutional Review Board. All study subjects were deceased,
no personally identifiable information was collected, and no effort
was made to contact living relatives. Record requests within each
jurisdiction were approved by the DC, MD, and VA state health
department institutional review boards.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We acknowledge Kathy Hudson from the Centers for Medicare and
Medicaid Services for her contribution to this work. This work was
presented as a poster at Renal Week 2008: American Society of
Nephrology (ASN) November 4–9, 2008, Philadelphia, Pennslyvania,
and at the VEITH Symposium on 18 November 2009.
Disclaimer
The findings and conclusions in this report are those of the author(s)
and do not necessarily represent the official position of the Centers
for Disease Control and Prevention.
REFERENCES
1. US Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic
Kidney Disease and End-Stage Renal Disease in the United States,
National Institutes of Health, National Institute of Diabetes and Digestive
and Kidney Diseases, Bethesda, MD. Available at: http://www.usrds.org/
2009/pdf/V2_00A_PRECIS_09.PDF.
2. Troidle L, Eisen T, Pacelli L et al. Complications associated with the
development of bacteremia with Staphylococcus aureus. Hemodial Int
2007; 11: 72–75.
3. Astor BC, Coresh J, Powe NR et al. Relation between gender and vascular
access complications in hemodialysis patients. Am J Kidney Dis 2000; 36:
1126–1134.
4. Winsett OE, Wolma FJ. Complications of vascular access for hemodialysis.
South Med J 1985; 78: 513–517.
5. Cohle SD, Graham MA. Sudden death in hemodialysis patients. J Forensic
Sci 1985; 30: 158–166.
6. Sandroni S. Venous needle dislodgement during hemodialysis: an
unresolved risk of catastrophic hemorrhage. Hemodial Int 2005; 9:
102–103.
7. Bachtell N, Goodell T, Grunkemeier G et al. Treatment of dialysis access
puncture wound bleeding with chitosan dressings. Dial Transplant 2006;
35: 654–732.
8. Undetected venous line needle dislodgement during hemodialysis can
be fatal. Health Devices 2003; 32: 325–326.
9. Marc B, Baudry F, Zerrouki L et al. Suicidal incised wound of a fistula for
hemodialysis access in an elderly woman: case report. Am J Forensic Med
Pathol 2000; 21: 270–272.
10. Byard RW. Forensic issues in cases of fatal hemorrhage from
arteriovenous dialysis access sites. Forens Sci Med Pathol 2007; 3:
128–132.
11. Ahlmen J, Gydell KH, Hadimeri H et al. A new safety device for
hemodialysis. Hemodial Int 2008; 12: 264–267.
12. Vincenti D, Aronica-Pollak PA, Sharfstein JM et al. Exsanguination
Associated with Vascular Access Sites in Hemodialysis Patients. American
Academy of Forensic Sciences Annual Meeting 2007 American Academy
of Forensic Sciences: San Antonio, TX.
13. Bor J. Dialysis deaths prompt warning: 24 patients in Md. died from
bleeding; precautions urged. The Baltimore Sun. 25 Jan 2007.
14. Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int
2007; 11: 178–189.
15. Xue JL, Dahl D, Ebben JP et al. The association of initial hemodialysis
access type with mortality outcomes in elderly Medicare ESRD patients.
Am J Kidney Dis 2003; 42: 1013–1019.
16. Charlson M, Szatrowski TP, Peterson J et al. Validation of a combined
comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251.
17. United States National Plan and Provider Enumeration System (NPPES)
March 2011 data dissemination. http://www.nppesdata.com/. Accessed
22 April 2011.
18. United States Renal Data System (USRDS) 2008 data. http://www.usrds.org/.
Accessed 22 April 2011.
19. National Kidney Foundation New York, NY. Hemodialysis Access.
Available at http://www.kidney.org/Atoz/content/hemoaccess.cfm.
20. National Kidney Foundation New York, NY.Hemodialysis Access: What
You Need to Know. Available at http://www.kidney.org/atoz/pdf/VA.pdf.
21. The Consumer Committee of the Southeastern Kidney Council. Available
at http://www.esrdnetwork6.org/utils/pdf/VAHemodialysis.pdf.
22. Vascular Access Work Group 2006. Clinical practice guidelines for vascular
access. Am J Kidney Dis 2006; 48 (Suppl 1): S248–S273.
23. Peters VJ, Clemons G, Augustine B. ‘Fistula First’ as a CMS breakthrough
initiative: improving vascular access through collaboration. Nephrol
Nurs J 2005; 32: 686–687.
692 Kidney International (2012) 82, 686–692
or ig ina l a r t i c l e KD Ellingson et al.: Vascular access hemorrhages in dialysis patients
